There are several issues related to the addition of new health apps to the Directory of Digital Health Applications (DiGAs) by the Federal Office for Drugs and Medical Devices (BfArM): …
Odelle Technology
-
News
-
If you suffer from chronic, painful knee osteoarthritis and have not found relief from conservative treatments, you may think that a knee replacement is your only option. But what if …
-
The Royal Marsdens Ana Ribeiro, AI Transformation Lead describes her background in imaging and how she moved into research, then leadership and management within research. She explains the AI Imaging …
-
Eli Lilly has launched LillyDirect, a novel service that provides US patients with direct access to some of its key prescription drugs for diabetes, migraine and obesity. The service also …
-
Two new dementia drugs could be available to patients in the UK in 2024, but the NHS might struggle to make them accessible. The healthcare system could face some problems …
-
Introduction Evidence-based healthcare decisions rely on rigorous and transparent assessments of the benefits and harms of medical drugs and procedures. The Institute for Quality and Efficiency in Health Care (IQWiG) …
-
The EU4Health initiative is a key source of funding for improving health outcomes across the EU. It has recently revealed some interesting details about its plans for supporting the National …
-
The Voluntary Scheme for Branded Medicines Pricing and Access in the UK is now presenting from senior industry executives in a recent article in 𝘛𝘩𝘦 𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭 𝘑𝘰𝘶𝘳𝘯𝘢𝘭. Comments along the lines of “Why …
-
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute for …
-
News
Switzerland is the first country in Europe to approve lurbinectedin for the treatment of small cell Lung Cancer
First approval in Europe for lurbinectedin. PharmaMar (MSE:PHM) has announced today that it has received the Temporary Authorisation for the commercialization of Zepzelca® (lurbinectedin) by the Swiss Agency for Therapeutic Products …